The European Medicines Agency granted an orphan drug designation to ImMucin for the treatment of multiple myeloma. ImMucin targets the less studied signal peptide domain of the MUC1 tumor antigen.
In the absence of the federal funding, cancer research will be leaning on private funders. But few private funders have the freedom to ask fundamental questions—questions whose answers may not have an immediate clinical impact but can dramatically advance scientific knowledge.
